Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma

Author:

Giacomelli Mauro1,Monti Matilde2,Pezzola Diego Cesare3,Lonardi Silvia2ORCID,Bugatti Mattia12,Missale Francesco24ORCID,Cioncada Rossella1,Melocchi Laura5ORCID,Giustini Viviana6,Villanacci Vincenzo1,Baronchelli Carla1,Manenti Stefania1,Imberti Luisa7ORCID,Giurisato Emanuele89ORCID,Vermi William1210ORCID

Affiliation:

1. Department of Pathology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy

2. Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

3. Department of Surgery, Surgery Division II, ASST Spedali Civili di Brescia, 25123 Brescia, Italy

4. Department of Head & Neck Oncology & Surgery Otorhinolaryngology, Antoni Van Leeuwenhoek—Nederlands Kanker Instituut, 1066 CX Amsterdam, The Netherlands

5. Department of Pathology, Fondazione Poliambulanza, 25124 Brescia, Italy

6. CREA Laboratory, AIL Center for Hemato-Oncologic Research, Diagnostic Department, ASST Spedali Civili di Brescia, 25123 Brescia, Italy

7. Section of Microbiology, University of Brescia, 25123 Brescia, Italy

8. Department of Biotechnology Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy

9. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK

10. Department of Pathology and Immunology, School of Medicine, Washington University, Saint Louis, MO 63130, USA

Abstract

Colorectal carcinoma (CRC) represents a lethal disease with heterogeneous outcomes. Only patients with mismatch repair (MMR) deficient CRC showing microsatellite instability and hyper-mutated tumors can obtain clinical benefits from current immune checkpoint blockades; on the other hand, immune- or target-based therapeutic strategies are very limited for subjects with mismatch repair proficient CRC (CRCpMMR). Here, we report a comprehensive typing of immune infiltrating cells in CRCpMMR. We also tested the expression and interferon-γ-modulation of PD-L1/CD274. Relevant findings were subsequently validated by immunohistochemistry on fixed materials. CRCpMMR contain a significantly increased fraction of CD163+ macrophages (TAMs) expressing TREM2 and CD66+ neutrophils (TANs) together with decrease in CD4−CD8−CD3+ double negative T lymphocytes (DNTs); no differences were revealed by the analysis of conventional and plasmacytoid dendritic cell populations. A fraction of tumor-infiltrating T-cells displays an exhausted phenotype, co-expressing PD-1 and TIM-3. Remarkably, expression of PD-L1 on fresh tumor cells and TAMs was undetectable even after in vitro stimulation with interferon-γ. These findings confirm the immune suppressive microenvironment of CRCpMMR characterized by dense infiltration of TAMs, occurrence of TANs, lack of DNTs, T-cell exhaustion, and interferon-γ unresponsiveness by host and tumor cells. Appropriate bypass strategies should consider these combinations of immune escape mechanisms in CRCpMMR.

Funder

A.I.A.C.C.I.O. Project

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3